hrp0098p1-291 | Thyroid 3 | ESPE2024

Response to TRIAC therapy in a child with Resistance to Thyroid Hormone beta and behavioural abnormalities

Ramakrishnan Anand , Jarvis Charlotte , Thomas Jay , Armitage Suzanne , Lyons Greta , Halsall David , Chatterjee Krishna , Ramakrishnan Renuka

Introduction: Resistance to thyroid hormone beta, a rare disorder due to mutation in thyroid hormone receptor β, results in raised thyroid hormones with non-suppressed TSH and variable symptoms. Manifestations of RTHb in childhood include failure to thrive, propensity to ENT infections and behavioural abnormalities including ADHD. We report biochemical and behavioural responses to therapy with triiodothyroacetic acid (TRIAC), a centrally-acting thyroid ho...

hrp0094p2-58 | Bone, growth plate and mineral metabolism | ESPE2021

Denosumab therapy for giant cell granuloma in a paediatric patient: using quantification of Tc99m-MDP uptake on SPECT imaging to guide treatment.

Wade Laura , Siddle Kathryn , Aderotimi Tobi , Armitage Suzanne , Blair Joanne , Munns Craig , Barnes Nik , Abernethy Laurence , Dharmaraj Poonam ,

Background: Giant cell granulomas (GCG) are uncommon bony lesions that most commonly affect the maxilla and mandible; whilst generally benign they can be disfiguring to the face. Historically, GCGs have been treated with steroids or bisphosphonates to try and avoid surgical resection. Over recent years denosumab, a human monoclonal antibody which acts against the receptor activator of nuclear factor kappa B ligand, has been shown to be effective in treating GC...